Singh, Prianka
Bristol-Myers Squibb (United States)
2 papers on CoChat
Most cited papers
- Verified
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Yau, T., Galle, P. R., Decaens, T., Sangro, B., Qin, S., da Fonseca, L. G., Karachiwala, H., Blanc, J.-F., Park, J.-W., Gane, E., et al. (2025) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 390
- Verified
Caregiver burden by treatment and clinical characteristics of patients with glioblastoma
Au, T. H., Willis, C., Reblin, M., Peters, K. B., Nghiemphu, P. L., Taylor, J. W., Colman, H., Cohen, A. L., Ormond, D. R., Chakravarti, A., et al. (2022) · Supportive Care in Cancer
Nursing care and researchCancer survivorship and care
Cited by 34
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free